How to access Ponvory from Saudi Arabia — the named-patient import pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-24

A Saudi patient with relapsing multiple sclerosis (MS) — including clinically isolated syndrome, relapsing-remitting, and active secondary-progressive disease — may receive a prescription for Ponvory (ponesimod) from their treating neurologist. Ponvory is FDA-approved, developed by Janssen, and is a recognised selective S1P1 receptor modulator option distinguished by once-daily oral dosing and a 14-day titration pack. In the Kingdom of Saudi Arabia, Ponvory is not routinely registered for outpatient dispensing, and access is typically coordinated through the named-patient import pathway via the Saudi Food and Drug Authority (SFDA).

This guide explains the pathway, documentation your physician prepares, typical timing and cost bands, and where Reserve Meds fits in.

The clinical situation

Ponvory is an orally active selective S1P1 receptor modulator. Selective S1P1 engagement (versus broader S1P1/3/4/5 activity of some older agents) is the class differentiator behind Ponvory's labelling profile. It is taken once daily. A 14-day gradual titration pack is used at initiation, stepping from 2 mg up to the 20 mg maintenance dose; the titration is designed to mitigate the first-dose cardiac-conduction signal characteristic of the class.

Eligibility requires a confirmed relapsing MS diagnosis per McDonald criteria, MRI evidence, and a clinical rationale. Before starting, your neurologist will establish a baseline ECG, review cardiac history, confirm complete blood count with lymphocyte count, baseline liver function tests, varicella serology, and ophthalmologic baseline (macular oedema risk). Live vaccines are avoided during therapy. Ongoing monitoring includes LFTs, lymphocyte count, and skin/ophthalmology surveillance.

Is Ponvory legally importable into Saudi Arabia?

Yes — through the SFDA named-patient import framework. The mechanism permits a Saudi-licensed physician to import a medicine not locally registered when (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent registered alternative is suitable, (c) the physician accepts clinical responsibility, and (d) chain of custody is documented. S1P-modulator named-patient imports for MS are a familiar category.

How the pathway works, step by step

1. Consultation with your treating neurologist. Confirmation of MS subtype, MRI review, prior DMT history, and clinical rationale for a selective S1P1 modulator.
2. Baseline workup. ECG, cardiac review, CBC with lymphocyte count, LFTs, varicella serology, ophthalmology baseline.
3. SFDA named-patient application. The physician or hospital pharmacy files the application including clinical rationale, patient reference, titration plan, and chain-of-custody commitment.
4. US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Ponvory from authorised distribution under DSCSA.
5. Ambient shipment. Ponvory ships under controlled ambient conditions with chain-of-custody documentation.
6. Arrival and first dose. The dispensing pharmacy releases the 14-day starter pack; first-dose cardiac monitoring is arranged per your neurologist's protocol.

What documentation your physician needs

• Clinical rationale letter confirming relapsing MS subtype and Ponvory as the indicated therapy
• Verification of Saudi medical licence (SCFHS)
• Baseline ECG report and cardiac review
• CBC with lymphocyte count and LFTs
• Varicella serology
• Ophthalmology baseline
• Planned titration schedule and monitoring plan

Reserve Meds provides a physician documentation kit bundling templates SFDA reviewers expect for S1P-modulator MS named-patient imports.

Typical costs and indicative timing

Ponvory's US cash-pay reference cost sits in an indicative 2026 annual range of roughly USD 90,000–105,000. International logistics, SFDA documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a transparent quote at the start of intake. These figures are indicative drug-only reference pricing, not guaranteed.

Indicative timing — not guaranteed — for first dispense after cohort intake opens is approximately 7–14 days from the moment a complete SFDA application is submitted. Monthly refills are generally faster once the pathway is established.

Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.

A brief culturally-aware note: Ramadan and Hajj seasons can affect scheduling and refill timing. Our concierge team coordinates the monthly cycle with your family's preferences.

Reserve Meds's role

• Sourcing. Through our US-licensed specialty wholesale partner under DSCSA chain-of-custody.
• Documentation. Regulatory package for your physician and SFDA review.
• Logistics. Ambient-controlled shipment to your prescribing hospital pharmacy.
• Concierge case lead. A named point of contact coordinating monthly refills.

What we do not do: we are not the prescriber, do not practise medicine, and are not the dispensing pharmacy. All clinical decisions remain with your treating neurologist. We operate on a waitlist basis during pre-launch.

Frequently asked

Is this legal in Saudi Arabia? Yes, when executed through the SFDA named-patient framework with appropriate documentation. See our trust and compliance page.

Why the 14-day titration pack? S1P-modulator therapy can cause first-dose bradycardia and transient conduction effects. Ponvory's gradual titration is designed to manage this and is part of standard FDA-labelled initiation.

Can I get live vaccines during therapy? Live vaccines are avoided during S1P-modulator therapy. Your neurologist will plan any vaccination updates before starting.

How does Ponvory compare with Zeposia, Mayzent, or fingolimod? All are S1P modulators for MS; receptor selectivity, half-life, titration, and indication approvals differ. Your neurologist selects based on disease subtype, comorbidity profile, and tolerability considerations.

Will private insurance cover this? Cash-pay is the default. Some Saudi private insurers consider named-patient imports case by case; we supply documentation but do not process claims directly.

Next step — join the first-cohort waitlist

Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we enter intake for Ponvory coordination in Saudi Arabia.

Add me to the Ponvory waitlist

Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.

---

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are in pre-launch; service availability is limited to our first cohort and published timelines are indicative, not guarantees. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.

Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-24.